Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis

ConclusionsOfatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.
Source: Pediatric Nephrology - Category: Urology & Nephrology Source Type: research